

Dr Henning Gädeke, the Chair of the Global Health EDCTP3 Joint Undertaking Governing Board
c/o Dr Michael Makanga, the Global Health EDCTP3 Joint Undertaking Executive Director
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d'Or
1060 Brussels
Belgium
29th September 2025

Letter of endorsement

Dear Sir/Madam,

On behalf of **Epicentre**, with registered address 14-34, avenue Jean Jaurès, 75019 Paris, France, SIREN 340 494 905 and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

Epicentre is an MSF Satellite dedicated to epidemiology and research.

Epicentre conducts field epidemiology activities, research projects and training sessions in support of Médecins Sans Frontières' (MSF) goals of providing medical assistance in areas where people are suffering from conflict, epidemics, disasters or where access to care is inadequate or non-existent.

Epicentre's strength lies in its ability to rapidly apply epidemiological methods in complex situations, thanks to its permanent teams in Paris (France), Maradi (Niger) and Mbarara (Uganda), as well as its teams of epidemiologists in MSF programs in Mali, DRC, Malawi, Chad, and South Sudan, and relocated in New York, Dubai, Dakar, Geneva, Brussels, London, and Cape Town. The research centers in Niger and Uganda provide the necessary infrastructure for a wide range of projects, which are designed to be applied in the field for the populations concerned and are often carried out in collaboration with leading research organisations and academic institutions.

In addition, **Epicentre** also trains MSF staff in epidemiology and public health tools. Through its training program, it helps equip staff with the tools and knowledge needed to deal with emergencies and epidemics.

Epicentre is committed to the objectives of Global Health EDCTP3 JU. Its experience of clinical trials and the essential activities necessary for their success mean it is regularly a partner in EDCTP projects. The **Epicentre** is part of the RAMP project submission, leading the Work Package 4, Data Management and Analysis.

Additionally, **Epicentre** will provide an **in-kind** investment in terms of expertise available from **key personnel**, such as senior scientific staff, referents for pharmacy and laboratory, research administration and technical support staff who are essential to the success of the RAMP project (160 000 EUR). We estimate the **total value of this in-kind contribution including indirect costs of 25% to be 200 000 EUR over the 60-month duration of the RAMP project.**

Epicentre

14-34, avenue Jean Jaurès – 75019 Paris - France
www.epicentre.msf.org

epimail@epicentre.msf.org
Tel + 33 (0)1 40 21 55 55

Association loi 1901
N° Siret 340 494 905 000 37
Code APE 7220Z

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes, and in particular, the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities, save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the "need-to-know" principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,

Dr Klaudia PORTEN
General Director, Epicentre
Paris, 29th September 2025

Porten
epicentre
14-34 Avenue Jean Jaurès, 75019 Paris
Tél. 01 40 21 55 55
epimail@epicentre.msf.org